Form D · Biotechnology
Rila Therapeutics, Inc.
South San Francisco, CA · CIK 0002051051
Offering snapshot reported Jan 7, 2025 · SEC filing
- Reported sold
- $6.98M Offering amount: $10.8M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 20, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 7, 2025 | Initial | $6,978,195 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-534373
The offering includes equity issued for consideration other than cash and as such the amounts entered are based on the issuer's good faith valuation of the consideration.
Source: Form D, filed Jan 7, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Dai | Director |
| Robert Drakas | Director, Executive |
| Michael Hui | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
280 Utah Avenue Suite 250
South San Francisco, CA, 94080
South San Francisco, CA, 94080